NCT07627620: Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
- State
- Not started
- Phase
- Phase 2
- People
- 54 planned
- Started
- 30 Jun 2026
- Primary completion
- 30 Sep 2027
- Arms
- Camrelizumab combined with famitinib malate and chemotherapy
- Results
- None posted
- 4 Jun 2026: Trial registered